Literature DB >> 33336505

The protective effect of isosteviol sodium on cardiac function and myocardial remodelling in transverse aortic constriction rat.

Qingjin Ke1, Fei Liu1, Yuxin Tang1, Jiedi Chen1, Hui Hu1, Xiaoou Sun1, Wen Tan1.   

Abstract

Pathological hypertrophy contributes to heart failure and there is not quite effective treatment to invert this process. Isosteviol has been shown to protect the heart against ischaemia-reperfusion injury and isoproterenol-induced cardiac hypertrophy, but its effect on pressure overload-induced cardiac hypertrophy is still unknown. Pressure overload induced by transverse aortic constriction (TAC) causes cardiac hypertrophy in rats to mimic the pathological condition in human. This study examined the effects of isosteviol sodium (STVNa) on cardiac hypertrophy by the TAC model and cellular assays in vitro. Cardiac function test, electrocardiogram analysis and histological analysis were conducted. The effects of STVNa on calcium transient of the adult rat ventricular cells and the proliferation of neonatal rat cardiac fibroblasts were also studied in vitro. Cardiac hypertrophy was observed after 3-week TAC while the extensive cardiac dysfunction and electronic remodelling were observed after 9-week TAC. Both STVNa and sildenafil (positive drug) treatment reversed the two process, but STVNa appeared to be more superior in some aspects and did not change calcium transient considerably. STVNa also reversed TAC-induced cardiac fibrosis in vivo and TGF-β1-induced fibroblast proliferation in vitro. Moreover, STVNa, but not sildenafil, reversed impairment of the autonomic nervous system induced by 9-week TAC.
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  autonomic nervous system; hypertrophy; isosteviol sodium; myocardial remodelling; transverse aortic constriction

Mesh:

Substances:

Year:  2020        PMID: 33336505      PMCID: PMC7812303          DOI: 10.1111/jcmm.16182

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.295


  50 in total

1.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

2.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

Review 3.  The origin of fibroblasts and mechanism of cardiac fibrosis.

Authors:  Guido Krenning; Elisabeth M Zeisberg; Raghu Kalluri
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 4.  beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy.

Authors:  E M Gilbert; S L Olsen; D G Renlund; M R Bristow
Journal:  Am J Cardiol       Date:  1993-03-25       Impact factor: 2.778

Review 5.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

6.  Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway.

Authors:  C Communal; K Singh; D R Pimentel; W S Colucci
Journal:  Circulation       Date:  1998-09-29       Impact factor: 29.690

7.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.

Authors:  G Michael Felker; Raymond L Benza; A Bleakley Chandler; Jeffrey D Leimberger; Michael S Cuffe; Robert M Califf; Mihai Gheorghiade; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

8.  Diabetic hyperglycemia attenuates sympathetic dysfunction and oxidative stress after myocardial infarction in rats.

Authors:  Christiane Malfitano; Catarina Andrade Barboza; Cristiano Mostarda; Renata Kelly da Palma; Camila Paixão dos Santos; Bruno Rodrigues; Sarah Cristina Ferreira Freitas; Adriane Belló-Klein; Susana Llesuy; Maria-Cláudia Irigoyen; Kátia De Angelis
Journal:  Cardiovasc Diabetol       Date:  2014-10-10       Impact factor: 9.951

9.  Isosteviol prevents the development of isoprenaline‑induced myocardial hypertrophy.

Authors:  Yaoxu Chen; Huimin Beng; Hao Su; Fuping Han; Zhuo Fan; Nanying Lv; Aleksandar Jovanović; Wen Tan
Journal:  Int J Mol Med       Date:  2019-09-17       Impact factor: 4.101

10.  STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.

Authors:  Fei Liu; Hao Su; Bo Liu; Ying Mei; Qingjin Ke; Xiaoou Sun; Wen Tan
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

View more
  1 in total

1.  The protective effect of isosteviol sodium on cardiac function and myocardial remodelling in transverse aortic constriction rat.

Authors:  Qingjin Ke; Fei Liu; Yuxin Tang; Jiedi Chen; Hui Hu; Xiaoou Sun; Wen Tan
Journal:  J Cell Mol Med       Date:  2020-12-17       Impact factor: 5.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.